Volume 155, Issue 4, Pages 712-719 (April 2019) Efficacy of Pirfenidone in the Context of Multiple Disease Progression Events in Patients With Idiopathic Pulmonary Fibrosis  Steven D. Nathan, MD, Ulrich Costabel, MD, Ian Glaspole, MB BS, PhD, Marilyn K. Glassberg, MD, Lisa H. Lancaster, MD, David J. Lederer, MD, Carlos A. Pereira, MD, Benjamin Trzaskoma, MS, Elizabeth A. Morgenthien, PhD, Susan L. Limb, MD, Athol U. Wells, MD  CHEST  Volume 155, Issue 4, Pages 712-719 (April 2019) DOI: 10.1016/j.chest.2018.11.008 Copyright © 2018 The Authors Terms and Conditions

Figure 1 Disease progression events up to 12 months in patients treated with pirfenidone vs placebo. *Pirfenidone, n = 623; placebo, n = 624. †In this graph, events were treated as independent even if they were recorded on the same calendar date. Dark shaded “caps” on each column depict the percentage of patients who had a second progression event of the same type. 6MWD = 6-min walk distance; %FVC = percent predicted forced vital capacity. CHEST 2019 155, 712-719DOI: (10.1016/j.chest.2018.11.008) Copyright © 2018 The Authors Terms and Conditions

Figure 2 A, B, Incidence and sequence of multiple disease progression events up to 12 months in patients treated with pirfenidone vs placebo who had more than one event. Patients were sorted by descending frequency of sequence within total number of events for those who received (A) pirfenidone or (B) placebo in the ASCEND and CAPACITY trials. *Events reported on the same calendar date (joined by + symbol) were treated as a single progression event. See Figure 1 legend for expansion of abbreviations. CHEST 2019 155, 712-719DOI: (10.1016/j.chest.2018.11.008) Copyright © 2018 The Authors Terms and Conditions

Figure 3 Time-to-multiple-events analysis: first and second events up to 12 months in patients treated with pirfenidone vs placebo. HR = hazard ratio. CHEST 2019 155, 712-719DOI: (10.1016/j.chest.2018.11.008) Copyright © 2018 The Authors Terms and Conditions